Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22261571 | 1.00 | CYP2C19 (0.39) | CYP2C19AKR1C1USP2ALDH1A1LMNA | |
| SCHEMBL2302547 | 0.97 | CYP2C19 (0.36) | CYP2C19AKR1C1FFAR3 | |
| SCHEMBL5281474 | 0.92 | — | — | |
| SCHEMBL1474791 | 0.86 | — | — | |
| SCHEMBL4590215 | 0.82 | ALDH1A1 (0.35) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL10002492 | 0.79 | USP2 (0.32) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL14128920 | 0.77 | ALDH1A1 (0.31) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL11098279 | 0.77 | CYP2C19 (0.38) | CYP2C19AKR1C1USP2ALDH1A1LMNA | |
| SCHEMBL648973 | 0.77 | CYP2C19 (0.38) | CYP2C19AKR1C1USP2ALDH1A1LMNA | |
| SCHEMBL31418724 | 0.77 | CYP2C19 (0.38) | CYP2C19AKR1C1USP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2080750-B1 | RADIATION-SENSITIVE COMPOSITION | MITSUBISHI GAS CHEMICAL CO (JP) | 2020-07-29 | — | — | EP | claimed |
| EP-3122356-A1 | TREATMENT OF PARKINSON'S DISEASE THROUGH ARFGAP1 INHIBITION USING SUBSTITUTED PIPERAZINE DERIVATIVES | Dalhousie University (CA) | 2017-02-01 | — | — | EP | claimed |
| US-20170020866-A1 | TREATMENT OF PARKINSON'S DISEASE THROUGH ARFGAP1 INHIBITION USING SUBSTITUTED PIPERAZINE DERIVATIVES | DALHOUSIE UNIVERSITY (CA) | 2017-01-26 | — | — | US | claimed |
| WO-2015154191-A1 | TREATMENT OF PARKINSON'S DISEASE THROUGH ARFGAP1 INHIBITION USING SUBSTITUTED PIPERAZINE DERIVATIVES | DALHOUSIE UNIVERSITY (CA) | 2015-10-15 | — | — | WO | claimed |
| EP-2350311-B1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | MADRIGAL PHARMACEUTICALS INC (US) | 2013-12-25 | — | — | EP | claimed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | claimed |
| EP-2350311-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2011-08-03 | — | — | EP | claimed |
| WO-2010056506-A1 | DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | claimed |
| EP-0399755-A1 | Light-sensitive composition and presensitized plate for use in making lithographic printing plates | Fuji Photo Film Co., Ltd. (JP) | 1990-11-28 | — | — | EP | claimed |
| WO-2023093728-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| CN-108008600-B | Radiation-sensitive composition | 三菱瓦斯化学株式会社 | 2021-02-09 | — | — | CN | disclosed |
| WO-2020229968-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2020-11-19 | — | — | WO | disclosed |
| US-10300055-B2 | Treatment of parkinson's disease through ARFGAP1 inhibition | DALHOUSIE UNIVERSITY (CA) | 2019-05-28 | — | — | US | disclosed |
| CN-104281006-B | Radiation-ray sensitive composition | 三菱瓦斯化学株式会社 | 2019-01-22 | — | — | CN | disclosed |
| US-4264467-A | Cyclic C6 compounds and their use in perfumes | FIRMENICH SA (CH) | 1981-04-28 | — | — | US | disclosed |
| US-4147672-A | Cyclic C6 ketones in perfumes | FIRMENICH SA (CH) | 1979-04-03 | — | — | US | disclosed |
| US-3968161-A | MULTISTAGE | FIRMENICH S.A. (CH) | 1976-07-06 | — | — | US | disclosed |
| US-3946078-A | ACIDIC DEHYDRATION | FIRMENICH SA (CH) | 1976-03-23 | — | — | US | disclosed |
| US-3931323-A | Process for the preparation of alkenoyl-substituted cyclohexenes | FIRMENICH SA (CH) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, MOGAT2 | CYP2C19 1036/4885AKR1C1 598/4885USP2 1856/4885 |
| US-10300055-B2 | Treatment of parkinson's disease through ARFGAP1 inhibition | ARFGAP1, ARF1, RAB1A | CYP2C19 4726/4885AKR1C1 4394/4885USP2 1019/4885 |
| US-20170020866-A1 | TREATMENT OF PARKINSON'S DISEASE THROUGH ARFGAP1 INHIBITION USING SUBSTITUTED PIPERAZINE DERIVATIVES | ARFGAP1, ARF1, ARF5 | CYP2C19 4698/4885AKR1C1 4452/4885USP2 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.